Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

24-month interim results of PANGAEA: A 5-year registry study evaluating long-term safety, efficacy and pharmacoeconomic data of German multiple sclerosis patients on fingolimod therapy
Multiple Sclerosis
(-)
152
Authors/Disclosures
Tjalf Ziemssen, MD, FÂé¶¹´«Ã½Ó³»­ (University Clinic Dresden)
PRESENTER
Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
Maria Diaz Lorente, MD (Novartis Pharma GmbH) No disclosure on file
Alexandra Fuchs, MD No disclosure on file
Zoltan Mari, MD, FÂé¶¹´«Ã½Ó³»­ (Cleveland Clinic Lou Ruro Center for Brain Health) Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Mari has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ACADIA. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Parkinson Study Group. Dr. Mari has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Dr. Mari has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for ACADIA. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for US World Meds. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Moore and Moore PLLC. Dr. Mari has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Francis Law Firm PLLC. Dr. Mari has stock in NeuroReserve. Dr. Mari has stock in Sensory Cloud. The institution of Dr. Mari has received research support from Cerevel. The institution of Dr. Mari has received research support from AbbVie. The institution of Dr. Mari has received research support from NIH. The institution of Dr. Mari has received research support from Parkinson's Foundation. The institution of Dr. Mari has received research support from Michael J Fox Foundation. The institution of Dr. Mari has received research support from LBDA. The institution of Dr. Mari has received research support from Eli Lilly.
Christian Cornelissen No disclosure on file